Illumina, Inc. — Q1 2014 Form 10-Q Summary
Business context and reporting period
Illumina develops, manufactures, and markets sequencing- and array-based life-science systems, instruments, consumables, services, and genetic-analysis tools. The filing covers the 13 weeks ended March 30, 2014, compared with the 13 weeks ended March 31, 2013. The company reports one operating and reportable segment.
Key financial metrics
| Metric | Q1 2014 | Q1 2013 | Change |
|---|---|---|---|
| Total revenue | $420.8 million | $331.0 million | Up 27.1% |
| Product revenue | $362.2 million | $296.2 million | Up 22% |
| Service and other revenue | $58.6 million | $34.8 million | Up 68% |
| Gross profit | $278.3 million | $219.3 million | Up 27% |
| Gross margin | 66.1% | 66.3% | Down 0.2 points |
| Income (loss) from operations | $92.1 million | $(45.1) million | Improved $137.2 million |
| Operating margin | 21.9% | (13.6)% | Improved |
| Net income (loss) | $60.0 million | $(22.6) million | Improved $82.6 million |
| Diluted EPS | $0.40 | $(0.18) | Improved |
| Cash flow from operations | $37.1 million | $87.8 million | Down $50.8 million |
Consumables revenue increased 18% to $242.5 million, instrument revenue increased 31% to $115.8 million, and service and other revenue increased 68% to $58.6 million. Excluding 2013 acquisitions, service and other revenue increased 38%.
Cash, cash equivalents, and short-term investments totaled approximately $1.1 billion at March 30, 2014, including $518.5 million of cash and cash equivalents and $573.3 million of short-term investments. Cash and cash equivalents held by foreign subsidiaries totaled approximately $413.2 million.
Current assets were $1.632 billion and total assets were $3.054 billion. Convertible debt principal outstanding was $920.0 million, consisting of the 0.25% convertible senior notes due March 2016. The notes had a carrying value of $848.0 million and were classified as current because of their conversion status. The notes became convertible on April 1, 2014 and are convertible through June 30, 2014. Management stated that available liquidity and expected operating cash flow should fund near-term needs for at least 12 months.
Material changes versus the prior comparable period
- Revenue growth was driven by higher sequencing consumable utilization, expansion of the instrument installed base, new instrument shipments, and acquired service businesses.
- Operating results benefited materially from the absence of the $105.9 million Syntrix-related operating expense recorded in Q1 2013 and the absence of $7.5 million of unsolicited tender-offer expenses.
- Research and development expense increased 25% to $77.0 million, while selling, general and administrative expense increased 29% to $109.6 million, primarily due to headcount, consulting, amortization, and acquired businesses.
- Gross margin declined slightly because of higher Syntrix-related legal charges recorded in cost of product revenue and a lower mix of higher-margin consumables, partly offset by improved instrument and service margins.
- The effective tax rate decreased to 28.4% from 52.5%, reflecting foreign earnings taxed at lower rates and discrete tax deductions related to stock awards.
- Operating cash flow declined primarily because Q1 2013 benefited from a $106.9 million increase in accrued legal contingencies, while Q1 2014 included a $52.2 million increase in accounts receivable.
- Investing cash use increased to $144.4 million from $65.0 million, mainly because of greater purchases of available-for-sale securities; Q1 2013 also included $345.1 million of net acquisition payments.
- The company repurchased 788,009 shares for $130.0 million in Q1 2014, compared with $25.0 million of repurchases in Q1 2013. Remaining repurchase authorization was approximately $237.5 million.
Guidance, outlook, risks, contingencies, and unusual items
The filing does not provide specific numerical revenue or earnings guidance. Management expects continued growth in sequencing demand and consumable revenue as the installed base expands, while anticipating continued investment in research and development and selling infrastructure. Management also expects future tax rates to trend below the U.S. federal statutory rate because of foreign earnings taxed at lower rates.
The company launched or announced new platforms during the period, including NextSeq 500 and HiSeq X Ten, and expects next-generation sequencing, reproductive health, applied markets, and other non-government-funded customers to support growth. Interim results are not necessarily indicative of full-year performance.
Syntrix Biosystems obtained a $115.1 million judgment related to alleged patent infringement and an ongoing 8% royalty on accused sales through patent expiration in September 2019. Illumina appealed, and Syntrix cross-appealed certain dismissed claims. Illumina accrued $138.8 million for the legal contingency at March 30, 2014, recorded a $5.8 million Q1 charge in cost of product revenue, and had deposited $17.8 million with the court for post-judgment royalties. The ultimate outcome remains uncertain.
Other risks include dependence on research funding, competition and technological change, product development and manufacturing execution, integration of acquisitions, taxation in multiple jurisdictions, foreign-exchange exposure, and litigation. The company reported no material changes to previously disclosed risk factors, no significant off-balance-sheet arrangements, and no material changes in internal control over financial reporting.
Important facts investors should verify
- Whether the 2016 convertible notes are converted, settled for cash and shares, or otherwise repaid, including the potential effect on liquidity and dilution.
- The status and financial impact of the Syntrix appeal, ongoing 8% royalty obligations, and any additional legal contingencies.
- Whether sequencing instrument placements translate into sustained consumable utilization and revenue growth.
- The sustainability of the 66.1% gross margin amid product mix changes, pricing pressure, royalties, and legal charges.
- The effect of continued acquisitions, integration costs, contingent consideration, and amortization on operating expenses and cash flow.
- The pace of share repurchases and the resulting impact on cash balances, share count, and earnings per share.
- Working-capital trends, particularly accounts receivable and inventory, given the decline in operating cash flow.